Aldeyra Therapeutics - ALDX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.33
  • Forecasted Upside: 124.36%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$4.16
▼ -0.09 (-2.12%)

This chart shows the closing price for ALDX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aldeyra Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALDX

Analyst Price Target is $9.33
▲ +124.36% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Aldeyra Therapeutics in the last 3 months. The average price target is $9.33, with a high forecast of $10.00 and a low forecast of $8.00. The average price target represents a 124.36% upside from the last price of $4.16.

This chart shows the closing price for ALDX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Aldeyra Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/21/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/19/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/17/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/17/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/16/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/3/2024OppenheimerUpgradeMarket Perform ➝ Outperform$10.00Low
4/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00Low
10/17/2023CitigroupLower TargetBuy ➝ Buy$25.00 ➝ $8.00Low
10/17/2023OppenheimerDowngradeOutperform ➝ Market PerformLow
8/9/2023OppenheimerReiterated RatingOutperform ➝ Outperform$14.00Low
6/30/2023HC WainwrightReiterated RatingBuy ➝ Buy$15.00Low
3/10/2023HC WainwrightReiterated RatingBuy$15.00Low
3/10/2023CitigroupBoost Target$23.00 ➝ $28.00Low
3/1/2023HC WainwrightReiterated RatingBuy$15.00Low
7/13/2022HC WainwrightReiterated RatingBuy$15.00Low
6/9/2022OppenheimerBoost Target$11.00High
6/9/2022CitigroupBoost TargetBuy$21.00 ➝ $26.00High
5/24/2022Berenberg BankInitiated CoverageBuy$28.00Low
4/27/2022HC WainwrightReiterated RatingBuy$15.00High
12/21/2021CitigroupLower TargetBuy$25.00 ➝ $21.00Low
12/21/2021SVB LeerinkLower TargetOutperform$24.00 ➝ $15.00High
12/1/2021SVB LeerinkReiterated RatingBuy$24.00High
4/28/2021CitigroupBoost Target$22.00 ➝ $25.00Low
4/25/2021SVB LeerinkReiterated RatingBuy$22.00High
3/12/2021SVB LeerinkInitiated CoverageOutperform$22.00High
2/8/2021HC WainwrightInitiated CoverageBuy$26.00High
12/16/2020Berenberg BankInitiated CoverageBuy$32.00High
11/6/2020Cantor FitzgeraldReiterated RatingOverweightLow
11/6/2020OppenheimerReiterated RatingBuyHigh
10/30/2020Jefferies Financial GroupInitiated CoverageBuy$24.00High
10/16/2020BTIG ResearchInitiated CoverageBuy$29.00High
9/22/2020Alliance Global PartnersInitiated CoverageBuy$32.00Medium
8/11/2020CitigroupLower TargetBuy$24.00 ➝ $22.00High
8/7/2020OppenheimerReiterated RatingBuy$15.00High
7/7/2020OppenheimerInitiated CoverageBuy$15.00Low
6/4/2020OppenheimerInitiated CoverageBuy$15.00Low
5/26/2020Janney Montgomery ScottReiterated RatingBuy ➝ Market Perform$28.00Low
5/26/2020LaidlawReiterated RatingBuy$30.00Low
5/20/2020OppenheimerInitiated CoverageBuy$12.00High
5/11/2020OppenheimerInitiated CoverageOutperform$12.00High
10/17/2019Cantor FitzgeraldReiterated RatingOverweight$33.00High
6/25/2019Cantor FitzgeraldSet TargetBuy$33.00Low
(Data available from 4/16/2019 forward)

News Sentiment Rating

0.94 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/18/2023
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
10/18/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/17/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
12/17/2023
  • 6 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/16/2024
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/15/2024
  • 7 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/16/2024
  • 5 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/15/2024

Current Sentiment

  • 5 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Aldeyra Therapeutics logo
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.
Read More

Today's Range

Now: $4.16
Low: $4.05
High: $4.33

50 Day Range

MA: $3.54
Low: $2.77
High: $4.72

52 Week Range

Now: $4.16
Low: $1.42
High: $11.97

Volume

496,380 shs

Average Volume

592,259 shs

Market Capitalization

$245.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.51

Frequently Asked Questions

What sell-side analysts currently cover shares of Aldeyra Therapeutics?

The following sell-side analysts have issued stock ratings on Aldeyra Therapeutics in the last year: Citigroup Inc., HC Wainwright, Oppenheimer Holdings Inc., and StockNews.com.
View the latest analyst ratings for ALDX.

What is the current price target for Aldeyra Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Aldeyra Therapeutics in the last year. Their average twelve-month price target is $9.33, suggesting a possible upside of 124.4%. Oppenheimer Holdings Inc. has the highest price target set, predicting ALDX will reach $10.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $8.00 for Aldeyra Therapeutics in the next year.
View the latest price targets for ALDX.

What is the current consensus analyst rating for Aldeyra Therapeutics?

Aldeyra Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ALDX will outperform the market and that investors should add to their positions of Aldeyra Therapeutics.
View the latest ratings for ALDX.

What other companies compete with Aldeyra Therapeutics?

How do I contact Aldeyra Therapeutics' investor relations team?

Aldeyra Therapeutics' physical mailing address is 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421. The biotechnology company's listed phone number is 781-761-4904 and its investor relations email address is [email protected]. The official website for Aldeyra Therapeutics is www.ampliphibio.com. Learn More about contacing Aldeyra Therapeutics investor relations.